JP2024175018A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024175018A5 JP2024175018A5 JP2024158746A JP2024158746A JP2024175018A5 JP 2024175018 A5 JP2024175018 A5 JP 2024175018A5 JP 2024158746 A JP2024158746 A JP 2024158746A JP 2024158746 A JP2024158746 A JP 2024158746A JP 2024175018 A5 JP2024175018 A5 JP 2024175018A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- pharmaceutical combination
- combination according
- alkyl
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862755196P | 2018-11-02 | 2018-11-02 | |
| US62/755,196 | 2018-11-02 | ||
| JP2021525039A JP7588855B2 (ja) | 2018-11-02 | 2019-11-04 | 治療方法 |
| PCT/US2019/059711 WO2020093061A1 (en) | 2018-11-02 | 2019-11-04 | Therapeutic methods |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021525039A Division JP7588855B2 (ja) | 2018-11-02 | 2019-11-04 | 治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024175018A JP2024175018A (ja) | 2024-12-17 |
| JP2024175018A5 true JP2024175018A5 (enExample) | 2025-04-14 |
Family
ID=70463345
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021525039A Active JP7588855B2 (ja) | 2018-11-02 | 2019-11-04 | 治療方法 |
| JP2024158746A Pending JP2024175018A (ja) | 2018-11-02 | 2024-09-13 | 治療方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021525039A Active JP7588855B2 (ja) | 2018-11-02 | 2019-11-04 | 治療方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220031847A1 (enExample) |
| EP (1) | EP3873530A4 (enExample) |
| JP (2) | JP7588855B2 (enExample) |
| KR (1) | KR20210120988A (enExample) |
| CN (1) | CN113365662A (enExample) |
| AU (1) | AU2019370563B2 (enExample) |
| BR (1) | BR112021008449A2 (enExample) |
| CA (1) | CA3118142A1 (enExample) |
| EA (1) | EA202191210A1 (enExample) |
| IL (1) | IL282794B2 (enExample) |
| MX (1) | MX2021005130A (enExample) |
| NZ (1) | NZ776256A (enExample) |
| SG (1) | SG11202104461XA (enExample) |
| WO (1) | WO2020093061A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109312342A (zh) * | 2016-04-11 | 2019-02-05 | 阿布特斯生物制药公司 | 靶向核酸偶联物组合物 |
| US20220062323A1 (en) * | 2018-11-02 | 2022-03-03 | Arbutus Biopharma Corporation | Bivalent targeted conjugates |
| EP4007811A2 (en) * | 2019-08-01 | 2022-06-08 | Alnylam Pharmaceuticals, Inc. | Carboxypeptidase b2 (cpb2) irna compositions and methods of use thereof |
| US20220387600A1 (en) * | 2019-12-06 | 2022-12-08 | Genevant Sciences Gmbh | Conjugates and methods for treating liver fibrosis |
| KR20220119052A (ko) * | 2019-12-20 | 2022-08-26 | 아뷰터스 바이오파마 코포레이션 | 합성 공정 및 중간체 |
| CN114901360A (zh) | 2019-12-20 | 2022-08-12 | 库瑞瓦格股份公司 | 用于递送核酸的新型脂质纳米颗粒 |
| KR20230118715A (ko) | 2020-10-14 | 2023-08-11 | 조지 메이슨 리서치 파운데이션 인코포레이티드 | 이온화 가능 지질 및 이의 제조 및 사용 방법 |
| EP4355756A4 (en) | 2021-06-18 | 2025-08-13 | Hongene Biotech Corp | N-ACETYLGALACTOSAMINE FUNCTIONALIZED NUCLEOSIDES |
| JP2024532271A (ja) | 2021-08-30 | 2024-09-05 | ホンジーン バイオテック コーポレイション | 官能化ｎ－アセチルガラクトサミンアナログ |
| CN117940158A (zh) | 2021-09-03 | 2024-04-26 | 库瑞瓦格欧洲公司 | 用于核酸递送的包含磷脂酰丝氨酸的新型脂质纳米颗粒 |
| WO2023097186A1 (en) * | 2021-11-24 | 2023-06-01 | The Regents Of The University Of California | Compositions and methods for enhancing visual function |
| CN118401539A (zh) | 2021-12-15 | 2024-07-26 | 兆维生物科技公司 | 官能化的n-乙酰半乳糖胺类似物 |
| CN118591552A (zh) * | 2022-01-30 | 2024-09-03 | 成都凌泰氪生物技术有限公司 | 一种配体、其制备方法及应用 |
| CA3246334A1 (en) * | 2022-03-25 | 2023-09-28 | Shanghai Hansoh Biomedical Co., Ltd. | BICYCLIC HETEROCYCLES AND THEIR LIGANDS FOR TARGETED ADMINISTRATION OF THERAPEUTIC AGENTS |
| US20250215042A1 (en) * | 2022-04-01 | 2025-07-03 | Genevant Sciences Gmbh | Mannose-targeted compositions |
| JP2025531872A (ja) * | 2022-09-12 | 2025-09-25 | ジェネバント サイエンシズ ゲーエムベーハー | 標的指向組成物 |
| EP4342460A1 (en) | 2022-09-21 | 2024-03-27 | NovoArc GmbH | Lipid nanoparticle with nucleic acid cargo |
| WO2024118503A1 (en) | 2022-11-28 | 2024-06-06 | Hongene Biotech Corporation | Functionalized n-acetylgalactosamine analogs |
| WO2024125597A1 (en) | 2022-12-14 | 2024-06-20 | Providence Therapeutics Holdings Inc. | Compositions and methods for infectious diseases |
| CN116535449B (zh) * | 2023-03-22 | 2025-09-16 | 华东理工大学 | 一种糖基没食子酸类衍生物及其制备方法与在制备乳腺癌靶向诊疗材料中的应用 |
| CN118993970B (zh) * | 2023-05-17 | 2025-12-23 | 苏州富士莱医药股份有限公司 | 一种l96侧链化合物的制备方法 |
| CN119219716A (zh) * | 2023-06-30 | 2024-12-31 | 上海维申医药有限公司 | 新型GalNAc的靶向递送片段及其制备和应用 |
| GB202311334D0 (en) * | 2023-07-24 | 2023-09-06 | Astrazeneca Ab | Multivalent cargo-carrying complexes and uses thereof |
| CN121752256A (zh) | 2023-09-01 | 2026-03-27 | 诺沃阿克有限责任公司 | 具有核酸负载物和可电离脂质的脂质纳米颗粒 |
| CN117624266A (zh) * | 2023-10-19 | 2024-03-01 | 弘亮(上海)生物医药科技有限公司 | 一种肝靶向化合物及其寡核苷酸缀合物、偶联方法与应用 |
| GB202408360D0 (en) | 2024-06-11 | 2024-07-24 | Cancer Research Tech Ltd | Tumour sensitisation |
| CN121045314B (zh) * | 2025-10-31 | 2026-04-14 | 南昌市第一医院 | 一种靶向降解hmgb1的化合物及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2404136T3 (es) * | 2008-05-13 | 2013-05-24 | University Of Washington | Ensamblajes micelares |
| WO2011062965A2 (en) * | 2009-11-18 | 2011-05-26 | University Of Washington Through Its Center For Commercialization | Targeting monomers and polymers having targeting blocks |
| AU2014296278C1 (en) * | 2013-07-30 | 2023-02-02 | Genevant Sciences Gmbh | Block copolymers and their conjugates or complexes with oligonucleotides |
| CN114642735A (zh) * | 2015-01-21 | 2022-06-21 | 菲泽尔克斯公司 | 用于将治疗剂和诊断剂递送到细胞中的方法、组合物和系统 |
| CN109312342A (zh) * | 2016-04-11 | 2019-02-05 | 阿布特斯生物制药公司 | 靶向核酸偶联物组合物 |
| US11684584B2 (en) * | 2016-12-30 | 2023-06-27 | Genevant Sciences Gmbh | Branched peg molecules and related compositions and methods |
| WO2018191278A2 (en) * | 2017-04-11 | 2018-10-18 | Arbutus Biopharma Corporation | Targeted compositions |
-
2019
- 2019-11-04 IL IL282794A patent/IL282794B2/en unknown
- 2019-11-04 EA EA202191210A patent/EA202191210A1/ru unknown
- 2019-11-04 CN CN201980087524.XA patent/CN113365662A/zh active Pending
- 2019-11-04 KR KR1020217016674A patent/KR20210120988A/ko not_active Ceased
- 2019-11-04 SG SG11202104461XA patent/SG11202104461XA/en unknown
- 2019-11-04 MX MX2021005130A patent/MX2021005130A/es unknown
- 2019-11-04 US US17/290,549 patent/US20220031847A1/en active Pending
- 2019-11-04 BR BR112021008449-5A patent/BR112021008449A2/pt unknown
- 2019-11-04 CA CA3118142A patent/CA3118142A1/en active Pending
- 2019-11-04 WO PCT/US2019/059711 patent/WO2020093061A1/en not_active Ceased
- 2019-11-04 NZ NZ776256A patent/NZ776256A/en unknown
- 2019-11-04 AU AU2019370563A patent/AU2019370563B2/en active Active
- 2019-11-04 JP JP2021525039A patent/JP7588855B2/ja active Active
- 2019-11-04 EP EP19880313.2A patent/EP3873530A4/en active Pending
-
2024
- 2024-09-13 JP JP2024158746A patent/JP2024175018A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2809481T3 (es) | Estructura de oligonucleótidos de tipo nanopartícula mejorada que tiene alta eficiencia y método para preparar la misma | |
| JP5952423B2 (ja) | 新規オリゴヌクレオチド接合体およびその用途 | |
| RU2015119409A (ru) | Конъюгаты олигонуклеотидов | |
| US9326941B2 (en) | High-efficiency nanoparticle-type double-helical oligo-RNA structure and method for preparing same | |
| US20220389430A1 (en) | Chemical modifications of small interfering rna with minimal fluorine content | |
| CN105188764B (zh) | Dna嵌入剂的细胞递送 | |
| AU2013246419A1 (en) | RNA aptamers for therapeutic and diagnostic delivery to pancreatic cancer cells | |
| RU2011154087A (ru) | Модуляторы гликопротеина vi, представляющие собой нуклеиновую кислоту | |
| JPWO2008096690A1 (ja) | ポリエチレングリコール誘導体 | |
| KR20180118716A (ko) | Ｄｂａｉｔ 분자의 전신 투여에 의한 암 치료법 | |
| US20250188467A1 (en) | Cancer stem cell marker and cancer stem cell targeting drug | |
| WO2015144736A1 (en) | Double-stranded rna conjugates and their use | |
| Yamazaki et al. | Multivalent mannose-conjugated siRNA causes robust gene silencing in pancreatic macrophages in vivo | |
| BR112021013369A2 (pt) | Moduladores de expressão de yap1 | |
| KR20230163998A (ko) | Wfdc2의 발현을 조절하는 안티센스 화합물 | |
| CA3118507A1 (en) | Modulators of foxp3 expression | |
| KR102613178B1 (ko) | Wfdc2의 발현을 조절하는 안티센스 화합물 | |
| Hazan-Halevy et al. | Extrahepatic delivery of RNA to immune cells | |
| Abdelaal | Enhancing miRNA Therapeutics Using Ligand Conjugated and Chemically Modified Tumor Suppressive miRNAs | |
| Tseng et al. | pH-responsive virus-drug conjugates for targeted PD-L1 silencing and enhanced cancer immunotherapy | |
| EP4243833A2 (en) | Gpc3 aptamers and variants and use thereof | |
| HK40052075A (en) | Cancer stem cell marker and cancer stem cell targeting drug | |
| KR20130080727A (ko) | 리간드가 결합된 이중나선 올리고 ｒｎａ 구조체 및 그 제조방법 |